Allspring Global Investments Boosts Gilead Sciences Stake

Institutional investor increases position in biopharmaceutical company by over 24%

Apr. 2, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Allspring Global Investments Holdings LLC, an institutional investor, increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.6% during the fourth quarter, according to a recent SEC filing. The firm now owns 363,563 shares of the biopharmaceutical company's stock, valued at $44.2 million.

Why it matters

Gilead Sciences is a major player in the pharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Institutional investors closely monitor the company's performance, and changes in their holdings can signal broader market trends and investor sentiment.

The details

According to the filing, Allspring Global Investments acquired an additional 71,872 shares of Gilead Sciences during the fourth quarter, bringing its total position to 363,563 shares. The firm's increased stake in Gilead suggests it sees potential for the company's growth and profitability going forward.

  • Allspring Global Investments increased its Gilead Sciences stake during the fourth quarter of 2025.

The players

Allspring Global Investments Holdings LLC

An institutional investor that manages a diversified portfolio of assets, including a significant position in the biopharmaceutical company Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

Allspring Global Investments' increased stake in Gilead Sciences suggests the institutional investor sees long-term potential in the biopharmaceutical company's growth and profitability, which could signal broader market confidence in Gilead's future performance.